Suppression of the Tie2 pathway using Trebananib, an investigational recombinant peptide-Fc fusion protein, or peptibody, that selectively binds to Ang1 and Ang2 and blocks their interaction with Tie2, is under active clinical investigation in various cancers, including breast, prostate, and ovarian. Here, ANGPT1 is linked to cancer.